PALISADE BIO INC

PALINASDAQ

🏆 #3545 by market capEarnings Nov 9US Equity

$920.69▼ $45.39 (−4.93%)

Simulated price

🔔

Track PALI

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.9%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$253M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

505.4x

Expensive

Otter Score

Weak

No chart data available for PALI.

Trading Snapshot

Day Range: $909.10 – $924.99
52-Week Range: $0.70 – $2.86
Volume: $3.78B
Avg Volume: $4.81B
Shares Outstanding: 173.6M
Next Earnings: Dec 13, 2026

Fundamentals Snapshot

Annual Revenue: $500,000
Last Q Revenue: $500,000
P/E Ratio: —
P/S Ratio: 505.4x
EPS (TTM): $-0.64
Dividend Yield: —
Dilution (1yr): +551.9%

Why Investors Own PALI

✓High-growth profile — revenue up -3.1% YoY with expanding US Equity exposure.
✓Healthy economics — 60% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PALISADE BIO INC

PALI

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$18M▲ +21.5% YoY

Free Cash Flow

−$11M▼ −11.0% YoY

Shares Outstanding

55.7M▲ +551.9% YoY

Net Cash

$133M▲ +$124M YoY

StockOtter · stockotter.space

About PALISADE BIO INC

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.

🦦